Elevation Oncology (ELEV)
(Real Time Quote from BATS)
$2.91 USD
+0.02 (0.69%)
Updated Jul 26, 2024 03:52 PM ET
After-Market: $2.94 +0.03 (1.03%) 4:14 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Income Statements
Fiscal Year end for Elevation Oncology, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 45 | 95 | 32 | 17 | 0 |
Income After Depreciation & Amortization | -45 | -95 | -32 | -17 | 0 |
Non-Operating Income | 0 | -1 | 0 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -46 | -95 | -32 | -17 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -46 | -95 | -32 | -17 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -46 | -95 | -32 | -17 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -46 | -95 | -32 | -17 | 0 |
Depreciation & Amortization (Cash Flow) | -1 | 0 | 0 | 0 | NA |
Income After Depreciation & Amortization | -45 | -95 | -32 | -17 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 34.08 | 23.27 | 12.13 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.34 | -4.09 | -2.64 | NA | NA |
Diluted Net EPS (GAAP) | -1.34 | -4.09 | -2.64 | NA | NA |
Fiscal Year end for Elevation Oncology, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 9.87 | 7.95 | 10.92 | 9.84 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -9.87 | -7.95 | -10.92 | -9.84 |
Non-Operating Income | NA | -0.83 | 0.06 | 0.30 | -0.27 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -10.70 | -7.89 | -10.63 | -10.11 |
Income Taxes | NA | 0.01 | 0.01 | 0.01 | 0.01 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -10.71 | -7.90 | -10.64 | -10.11 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -10.71 | -7.90 | -10.64 | -10.11 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 47.37 | 42.42 | 42.40 | 27.58 |
Diluted EPS Before Non-Recurring Items | NA | -0.23 | -0.19 | -0.25 | -0.37 |
Diluted Net EPS (GAAP) | NA | -0.23 | -0.19 | -0.25 | -0.37 |